NCT00901069

Azacitidine With Rituximab, Vincristine, and Cyclophosphamide in Refractory Lymphoma

Azacitidine With Rituximab, Vincristine, and Cyclophosphamide in Refractory Lymphoma: A Phase I Trial

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 12 (actual)
• Sponsor: Shams Shakil · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a phase I, prospective, open label, dose escalation study of azacitidine in combination with rituximab, vincristine, and cyclophosphamide for the treatment of refractory lymphoma. The investigators expect to enroll 12-24 patients in this trial over a 2 year accrual period.

Conditions

• Lymphoma
• Hodgkin Disease
• Lymphoma, Non-Hodgkin

Interventions

Type	Name	Description
DRUG	Azacitidine with rituximab, vincristine, and cyclophosphamide	Azacitidine cycle days 1-5 Cyclophosphamide cycle days 6-9 Vincristine cycle day 8 Rituximab cycle day 8 Rituximab is only for those patients with CD20+ lymphoma. Azacitidine 25 mg/m2\^ Azacitidine 50 mg/m2\^ Azacitidine 75 mg/m2\^ Azacitidine 100 mg/m2\^

Timeline

• Start date: 2009-05-01
• Primary completion: 2012-01-01
• Completion: 2012-11-01
• First posted: 2009-05-13
• Last updated: 2016-10-17

Locations

1 site across 1 country: United States